Evidence map›Paper›PMID 38465225›Full record

ReviewAdvanced genetics (Hoboken, N.J.)2024

Genome Engineering as a Therapeutic Approach in Cancer Therapy: A Comprehensive Review.

Jack Gemayel, Alain Chebly, Hampig Kourie, Colette Hanna, Kayane Mheidly, Melissa Mhanna, Farah Karam, Daniel Ghoussaini, Paula El Najjar, Charbel Khalil

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced genetics (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jack GemayelFaculty of Sciences Balamand University Beirut Lebanon.
Alain CheblyCenter Jacques Loiselet for Medical Genetics and Genomics (CGGM), Faculty of Medicine Saint Joseph University Beirut Lebanon.
Hampig KourieCenter Jacques Loiselet for Medical Genetics and Genomics (CGGM), Faculty of Medicine Saint Joseph University Beirut Lebanon.
Colette HannaFaculty of Medicine Lebanese American University Medical Center Rizk Hospital Beirut Lebanon.
Kayane MheidlySheikh Shakhbout Medical City Abu Dhabi UAE.
Melissa MhannaFaculty of Medicine Paris Saclay University 63 Rue Gabriel Péri Le Kremlin-Bicêtre 94270 France.
Farah KaramFaculty of Medicine Balamand University Beirut Lebanon.
Daniel GhoussainiFaculty of Medicine Balamand University Beirut Lebanon.
Paula El NajjarFMPS Holding BIOTECKNO s.a.l. Research and Quality Solutions Naccash Beirut 60 247 Lebanon.
Charbel KhalilReviva Regenerative Medicine Center Bsalim Lebanon.ORCID https://orcid.org/0000-0001-7740-6963

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is one of the foremost causes of mortality. The human genome remains stable over time. However, human activities and environmental factors have the power to influence the prevalence of certain types of mutations. This goes to the excessive progress of xenobiotics and industrial development that is expanding the territory for cancers to develop. The mechanisms involved in immune responses against cancer are widely studied. Genome editing has changed the genome-based immunotherapy process in the human body and has opened a new era for cancer treatment. In this review, recent cancer immunotherapies and the use of genome engineering technology are largely focused on.

Indexed as

cancerCAR‐Tgenome editingimmunotherapytherapeutic tool

Identifiers

PMID38465225
PMCPMC10919288

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.